Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study.
Efficacy and safety of treatment with imidacloprid 10%+moxidectin 2.5% spot-on (Advocate, Advantage multi; Bayer AG, Leverkusen, Germany) were tested in dogs naturally infested with Sarcoptes scabiei or Otodectes cynotis in a multi-centre, controlled, randomized, blinded field study conducted in France, Germany, Albania and the UK. The study was performed according to a non-inferiority design to demonstrate that the efficacy of imidacloprid/moxidectin spot-on was not inferior to that of a control product containing selamectin (Stronghold spot-on; Pfizer). All Sarcoptes-infested dogs were topically treated twice (days 0 and 28) with the dosage recommended by the respective manufacturer (27 dogs with imidacloprid/moxidectin, 26 with selamectin). All Otodectes-infested dogs were treated on day 0 (35 dogs with imidacloprid/moxidectin, 34 with selamectin), and only those still positive on day 28 received a second treatment. Parasitological cure rate in Sarcoptes-infested dogs was 100% for both treatments, while parasitological cures rates in the Otodectes-infested dogs at day 28 and day 56 were 68.6 and 85.7% with imidacloprid/moxidectin, and 64.7 and 88.2% with Stronghold. Non-inferiority of Advocate was confirmed statistically. Clinical assessment of skin lesion scores at day 56 showed that with either product >96% of the dogs treated against sarcoptic mange were improved or cured, the difference between the groups being non-significant. On the basis of a final clinical assessment of lesion scores, 80% of the dogs treated with imidacloprid/moxidectin against otoacariosis and 85.3% of those treated with selamectin were rated cured or improved. Only three mild, possibly drug-related adverse reactions were observed among alI treated animals (two in the imidacloprid/moxidectin group, one in the selamectin group). It is concluded that imidacloprid/moxidectin spot-on is an effective and safe treatment for sarcoptic mange and otoacariosis in the dog.
Krieger
K
K
Bayer HealthCare AG, Animal Health, R&D Parasiticides, 51368, Leverkusen, Germany. klemens.krieger@bayerhealthcare.com.
Heine
J
J
Bayer HealthCare AG, Animal Health, R&D Parasiticides, 51368, Leverkusen, Germany.
Dumont
P
P
Datavet S.A., 48 impasse des Eglantiers, 34980, Saint Clement de Riviere, France.
Hellmann
K
K
Klifovet AG, Geyerspergerstrasse 27, 80689, München, Germany.
D000287:Administration, Topical; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004359:Drug Therapy, Combination; D004427:Ear Diseases / Q000469:parasitology / Q000662:veterinary; D005260:Female; D007093:Imidazoles / Q000008:administration & dosage* / Q000627:therapeutic use*; D007306:Insecticides / Q000008:administration & dosage / Q000627:therapeutic use; D007559:Ivermectin / Q000031:analogs & derivatives / Q000627:therapeutic use; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008924:Mite Infestations / Q000188:drug therapy / Q000662:veterinary*; D000073943:Neonicotinoids; D009574:Nitro Compounds / Q000008:administration & dosage* / Q000627:therapeutic use*
D007093:Imidazoles; D007306:Insecticides; D018942:Macrolides; D000073943:Neonicotinoids; D009574:Nitro Compounds; C082359:imidacloprid; D007559:Ivermectin; C414354:selamectin; C027837:moxidectin